Audit Trail Review by Exception in FDA-Regulated Environments: Reducing Review Burden While Strengthening Data Integrity

Overview

Audit trails are essential to maintaining trustworthy electronic records in FDA-regulated environments—but reviewing them can quickly become one of the most resource-intensive compliance activities. As systems generate increasing volumes of electronic data and associated audit-trail entries, organizations often rely on exhaustive manual reviews that consume valuable Quality resources, contribute to reviewer fatigue, delay critical decisions, and can make genuinely significant events harder to identify.

At the same time, audit-trail weaknesses remain a significant data integrity concern. Disabled audit trails, unauthorized or unexplained changes, inappropriate user privileges, deleted data, missing change justifications, and inadequate review procedures can undermine the reliability of electronic records and create serious inspection risks.

The challenge, therefore, is not simply whether audit trails should be reviewed, but how to review them efficiently while maintaining a defensible level of control.

This session examines a risk-based “review by exception” approach that helps organizations focus reviewer attention on events most likely to affect data integrity, product quality, patient safety, security, or regulatory compliance. Rather than treating every audit-trail entry as equally significant, organizations can establish meaningful risk criteria, identify high-risk events and red flags, and develop review processes that reduce unnecessary effort without weakening oversight.

Attendees will explore how review by exception can be integrated with modern Computer Software Assurance (CSA) and risk-based validation practices, along with the use of automation, AI-enabled analytics, and advanced monitoring tools to identify anomalies and prioritize records requiring human attention.

The session will also examine the critical role of the Expert-in-the-Loop, ensuring that automation supports—not replaces—experienced human judgment. Participants will leave with practical considerations for designing an audit-trail review program that is more efficient, inspection-ready, scalable, and capable of identifying the events that truly matter.

Areas covered in the session:

• Regulatory Expectations and Industry Drivers
• Understanding the Purpose of Audit Trail Review
• Review by Exception Principles
• High-Risk Events and Red Flags
• Reducing Reviewer Burden Without Losing Control
• Leveraging AI and Advanced Analytics
• Integration with CSA and Modern Validation Approaches
• Inspection Readiness and Defensibility
• Practical Implementation Roadmap
• Future State of Audit Trail Review
• Q&A

To support implementation of the concepts discussed during the webinar, attendees will receive the following handouts:

• Audit Trail Review-by-Exception Scenario Workbook
• Audit Trail Red-Flag Investigation & Inspection Readiness Toolkit

Who will benefit?

Audit trail review is a critical part of maintaining data integrity and inspection readiness in FDA-regulated environments, but traditional review methods can become time-consuming, repetitive, and increasingly difficult to manage as electronic data volumes grow.

This session will show you how a risk-based review by exception approach can reduce unnecessary reviewer effort while directing attention to high-risk events, unusual changes, and potential issues that may affect compliance, product quality, or data integrity. You will also learn how automation, AI-enabled analytics, and modern Computer Software Assurance practices can support a more efficient and defensible review process.

You will benefit from the practical perspective of Carolyn Troiano, who brings more than 45 years of experience in computer system validation across pharmaceutical, medical device, biotechnology, and other FDA-regulated industries. Having participated in the FDA/Industry Partnership that helped develop 21 CFR Part 11, and with more than three decades of training professionals on CSV, Part 11, and Data Integrity, Carolyn will help attendees connect regulatory expectations with practical approaches they can apply within their own organizations.

Who will benefit?

This webinar is designed for professionals responsible for data integrity, computerized systems, audit trail oversight, validation, and FDA compliance in pharmaceutical, biotechnology, medical device, and other regulated life sciences organizations. Those who will benefit most include:

• Quality Assurance (QA) Managers and Directors
• Quality Systems Managers
• Computer System Validation (CSV) Managers and Specialists
• Computer Software Assurance (CSA) Leads and Specialists
• Data Integrity Managers and Specialists
• 21 CFR Part 11 Compliance Specialists
• GxP IT Quality and Compliance Managers
• Validation Engineers and Validation Specialists
• Computerized System Owners and Application Owners
• Laboratory Systems / LIMS Managers and Administrators
• Manufacturing Systems / MES Quality and Compliance Professionals
• Electronic Records and Data Governance Professionals
• QA Auditors and Internal Compliance Auditors
• IT Professionals Supporting GxP-Regulated Systems
• FDA Compliance and Regulatory Compliance Professionals